Swiss pharmaceutical and diagnostics giant Roche is deepening its push into artificial intelligence-powered healthcare, agreeing to acquire U.S.-based PathAI in a transaction valued at up to $1.05 billion, as global drugmakers race to embed AI deeper into disease detection and personalized medicine. Under the agreement announced Thursday, Roche will pay $750 million upfront for the
Don't miss out on breaking stories and in-depth articles.
